Clinical trials: Advanced Digestive System Tumor
Gastric Carcinoma
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
Cisplatin, an intravenously administered platinum agent, in combination with an intravenously administered taxane and capecitabine has been shown to improve time to disease progression and overall survival in previously untreated…
- Trial name
- NCT01348009
- Testing
- Tesetaxel-capecitabine-cisplatin
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Genta Incorporated
Gastric and Colorectal Cancer
A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
This study is a prospective single-arm phase II clinical study. Advanced gastric and colorectal tumor patients with FGFR 1-3 alterations who have failed standard therapy will be enrolled in this study once they have signed the…
- Trial name
- NCT05202236
- Testing
- pemigatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Biliary Tract Cancer
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Phase II Study of Refametinib, a MEK inhibitor, as second-line treatment in advanced biliary tract adenocarcinoma
- Trial name
- NCT02346032
- Testing
- refametinib
- Volunteers
- 4 people
- Sponsor
- Samsung Medical Center
Metastatic Pancreatic Cancer
Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer
This research study uses radiation or a gene therapy agent, TNFerade in addition to a dendritic cell vaccine in patients with locally advanced or low volume metastatic pancreatic cancer.
- Trial name
- NCT00868114
- Testing
- KLH-pulsed autologous dendritic cell vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Leo W. Jenkins Cancer Center
Pancreatic Cancer
Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer
The purpose of this study is to identify a dose of P276-00 that can be safely administered along with Gemcitabine and to examine safety and efficacy of the combination in treatment of advanced pancreatic cancer.
- Trial name
- SAVIOR (NCT00898287)
- Testing
- P276-00, Gemcitabine
- Where
- 7 sites in India
- Volunteers
- 23 people
- Sponsor
- Piramal Enterprises Limited
Colorectal Cancer
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy…
- Trial name
- APOLLON (NCT02613221)
- Testing
- Panitumumab + TAS-102
- Where
- 32 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Esophageal Neoplasms
Docetaxel and S-1 for Advanced Esophageal Cancer
This study will evaluate the efficacy of docetaxel and S-1 combination chemotherapy in Korean patients with esophageal cancer.
- Trial name
- NCT01693432
- Testing
- DS (docetaxel+S-1)
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Hallym University Medical Center
Gastric Adenocarcinoma, Gastric Cancer
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Gastric adenocarcinoma is the 4th most frequent cancer and the 2nd leading cause of cancer mortality. Most of the patients have metastatic, locally advanced or recurrent unresectable disease.
- Trial name
- NCT03959293
- Testing
- Durvalumab, Tremelimumab, FOLFIRI Protocol
- Where
- 35 sites in France
- Volunteers
- 107 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Carcinoma
Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer
The study "Phase I trial of Adoptive T cell Therapy with Activated P53 specific T cells for Treatment of Advanced Colorectal Cancer" is an open label, single arm trial.
- Trial name
- ATACC (NCT02577588)
- Testing
- re-activated T cells
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Gastric Cancer
Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
The purpose of this study is to determine which Arm (capecitabine + irinotecan versus capecitabine + cisplatin) shows higher response rates in the treatment of advanced gastric-oesophagal cancer Furthermore, comparison of…
- Trial name
- NCT00675194
- Testing
- Cisplatin, Irinotecan, Capecitabine
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Johannes Gutenberg University Mainz
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Neoadjuvant Therapy
Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
Apatinib has been proved to be effective and safe among patients in advanced colorectal cancer in several trials. the investigators aimed to evaluate its efficacy and safety as the neoadjuvant therapy in real world practice, and…
- Trial name
- NCT03377842
- Testing
- FOLFOX regimen, apatinib and FOLFOX regimen
- Volunteers
- 100 people
- Sponsor
- Sichuan Provincial People's Hospital
Locally Advanced Hepatocellular Carcinoma
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
The proposed study is an open-label, single institution, single arm phase 1b study of neoadjuvant cabozantinib plus nivolumab in patients with locally advanced HCC.
- Trial name
- NCT03299946
- Testing
- Cabozantinib, Nivolumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesylate (current standard therapy)…
- Trial name
- NCT00385203
- Testing
- AZD2171
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Cervical Cancer, HPV Cancers
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
Background: More than 30,000 cases of human papillomavirus (HPV) associated cancers occur annually in the United States. When these cancers spread, they do not respond well to standard treatments and are often incurable.
- Conditions
- Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04287868
- Testing
- PDS0101, M7824, NHS-IL12
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Radiotherapy
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
PD-1 inhibitor plus anti-VEGFR has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, PD-1 Inhibitors
- Trial name
- NCT06708650
- Testing
- Combination of SFRT, PD-L1 inhibitor, and Anti-VEGF
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guiping People's Hospital
Esophageal Carcinoma
Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
The standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) is definitive concurrent chemoradiotherapy (CCRT).
- Trial name
- NCT07034118
- Testing
- Proton radiotherapy, Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Anhui Provincial Hospital
Esophageal Squamous Carcinoma Cell
A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
Effective later-line treatment options remain an unmet medical need for patients with advanced esophageal squamous cell carcinoma (ESCC) whose disease has progressed after prior immunotherapy, particularly given the widespread…
- Trial name
- NCT07688291
- Testing
- PD-1/IL-2α-bias bispecific antibody fusion protein
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing GoBroad Hospital
Colorectal Cancer, Advanced Adenoma
China Colorectal Cancer Screening Trial 1 (C-Cost1)
Colorectal cancer (CRC) is one of the most common malignancies in China. Currently, its incidence rate is increasing at a rate of 4% per year, exceeding the global annual average growth rate.
- Trial name
- NCT07090291
- Testing
- Colonoscopy, FIT, Blood test
- Where
- 7 sites in China
- Volunteers
- 60,300 people
- Sponsor
- Zhejiang University
Colorectal Cancer
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Vaccines may make the body build an immune response that will kill cancer cells. Combining vaccine therapy with interleukin-2 may kill more cancer cells.
- Trial name
- NCT00019591
- Testing
- aldesleukin, ras peptide cancer vaccine, adjuvant therapy
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.